9 Amendments of Miriam DALLI related to 2018/2775(RSP)
Amendment 1 #
Recital A
A. whereas the Cannabis plant is made of more than 480 compounds which include more than 100 cannabinoids constituted of both psychoactive and non- psychoactive compounds. Many of the compounds constituting the Cannabis plant are unique to Cannabis;
Amendment 3 #
Recital B a (new)
Ba. whereas the cannabis plant constitutes of a numerous other cannabinoids such as Cannabichromene, Cannabinol, Cannabidiolic Acid, Cannabigerol and Tetrahydrocannabivarin, which can have neuroprotective effects, can contribute to the decrease of certain symptoms affecting patients such as chronic pain, inflammation, bacterial infections and stimulate bone growth.
Amendment 19 #
Recital J
J. whereas a review of existing scientific literature on the subject of medical cannabis provides conclusive or substantial evidence that cannabis and cannabinoids have therapeutic effects such as in the treatment of chronic pain in adults (e.g. in cancer diseases), as antiemetics in the treatment of chemotherapy-induced nausea and vomiting or for improving patient- reported multiple sclerosis spasticity symptoms and is effective in the treatment of patients with anxiety disorders, PTSD and depression;
Amendment 26 #
Recital K
K. whereas there is limited evidence that cannabis or cannabinoids are effective for increasing appetite and decreasing weight loss associated with HIV/AIDS, improving clinician-measured multiple sclerosis spasticity symptoms, improving symptoms of Tourette syndrome, improving symptoms of posttraumatic stress disorder;
Amendment 29 #
Recital N
N. whereas there is no uniform standardisation system for the labelling of the drugs that contain THC and CBD, CBD and other cannabinoids found within the cannabis plant; ;
Amendment 33 #
Recital O
O. whereas there is little or no educational training on the impact of medical products containing THC and CBD in EU countries for medical staff - medical students, medical doctors and pharmacists, psychiatrists, as well as social campaigns for young people and women who have motherhood in their perspective;
Amendment 53 #
Paragraph 4 a (new)
4a. Calls on the Commission and Member States to embark on more research and stimulate innovation with regards to projects related to the use of cannabis for medicinal purposes.
Amendment 60 #
Paragraph 6
6. Calls on the Commission to establish a network which would bring together both EMA and the EMCDDA as well as responsible national authorities and patient organisations, civil society, social partners, consumer organisations, healthcare professionals and NGOs together with other relevant stakeholders to ensure an effective implementation of the strategy for cannabis-based medicines;
Amendment 68 #
Paragraph 8 a (new)
8a. Emphasises that to ensure that patients have access to the right therapy, which is case specific and caters towards their individual needs as patients with single or multiple disorders, it is essential to ensure that patients are provided with comprehensive information about the full spectrum profiles of the plant strains used within the medication provided. Such information would empower patients and medical practitioners to prescribe medication which takes into consideration the holistic needs to the patient and corresponding therapy;